After emerging from the shadows with a $100 million Series A in April, Seaport Therapeutics has moved ... Seaport said the money would support a pipeline of improved neuropsychiatric drug ...

The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport Therapeutics. Karuna co-founder Daphne ...

About Seaport Therapeutics Seaport Therapeutics is a ... All the therapeutic candidates in its pipeline of potentially first and best-in-class medicines are based on the Glyph platform, which ...

Winners include Metsera, COUR Pharmaceuticals, Mirador and Seaport Therapeutics. "This year's NextGen class hits on all the hot areas, from GLP-1s in weight loss to ADCs in cancer and cell therapy ...

Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage ... All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is ...